Skip to main
PRTA
PRTA logo

Prothena (PRTA) Stock Forecast & Price Target

Prothena (PRTA) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 13%
Sell 13%
Strong Sell 0%

Bulls say

Prothena Corp PLC is advancing its clinical pipeline with promising investigational therapeutics aimed at addressing significant neurodegenerative and rare diseases, such as AQ amyloidosis, Parkinson's disease, and Alzheimer's. The company has forecasted the potential to earn up to $105 million in aggregate milestones by 2026 from collaborations with Novo Nordisk and Bristol-Myers Squibb, indicating strong potential revenue growth tied to product development advancements. Additionally, despite some safety concerns regarding elevated ARIA levels, products like PRX012 have demonstrated favorable efficacy profiles and good tolerability, supporting a positive outlook for the company’s future performance.

Bears say

Prothena Corp PLC is facing a challenging outlook due to its ongoing net losses, which are expected to persist until at least the approval and commercialization of its therapeutic products, potentially extending into the early launch phase. The company's reliance on additional capital raises poses an uncertain and dilutive impact on shareholder value, complicating its financial stability. Furthermore, regulatory risks associated with the changing stance on drug approvals for specific diseases and molecular classes may present significant obstacles to the company's success.

Prothena (PRTA) has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Prothena and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Prothena (PRTA) Forecast

Analysts have given Prothena (PRTA) a Buy based on their latest research and market trends.

According to 8 analysts, Prothena (PRTA) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Prothena (PRTA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.